Work

Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.6070

Authors: Adam Luginbuhl, Jennifer Maria Johnson, Elizabeth R Scott, Larry Harshyne, Elizaveta Flerova Flerova, Madalina Tuluc, Stacey Gargano, Benjamin Leiby, Matthew O. Old, Nolan Seim, Joseph M. Curry, David M. Cognetti, Athanassios Argiris

Institutions: Thomas Jefferson University, Thomas Jefferson University Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Sidney Kimmel Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4293074251

Cites:

Cited by: 9

Related to: 10